DK0773228T3 - Fremgangsmåde til fremstilling af monoklonale human-antistoffer og deres anvendelse - Google Patents

Fremgangsmåde til fremstilling af monoklonale human-antistoffer og deres anvendelse

Info

Publication number
DK0773228T3
DK0773228T3 DK96117361T DK96117361T DK0773228T3 DK 0773228 T3 DK0773228 T3 DK 0773228T3 DK 96117361 T DK96117361 T DK 96117361T DK 96117361 T DK96117361 T DK 96117361T DK 0773228 T3 DK0773228 T3 DK 0773228T3
Authority
DK
Denmark
Prior art keywords
monoclonal antibodies
human monoclonal
preparation
antibody
switched
Prior art date
Application number
DK96117361T
Other languages
English (en)
Inventor
Georg Wilhelm Prof Bornkamm
Dirk Priv Doz Dr Eick
Bettina Dr Kempkes
Nicola Maria Jochner
Original Assignee
Gsf Forschungszentrum Umwelt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gsf Forschungszentrum Umwelt filed Critical Gsf Forschungszentrum Umwelt
Application granted granted Critical
Publication of DK0773228T3 publication Critical patent/DK0773228T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK96117361T 1995-11-09 1996-10-29 Fremgangsmåde til fremstilling af monoklonale human-antistoffer og deres anvendelse DK0773228T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19541844A DE19541844C1 (de) 1995-11-09 1995-11-09 Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung

Publications (1)

Publication Number Publication Date
DK0773228T3 true DK0773228T3 (da) 2002-07-22

Family

ID=7777063

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96117361T DK0773228T3 (da) 1995-11-09 1996-10-29 Fremgangsmåde til fremstilling af monoklonale human-antistoffer og deres anvendelse

Country Status (6)

Country Link
US (1) US5798230A (da)
EP (1) EP0773228B1 (da)
AT (1) ATE215563T1 (da)
DE (2) DE19541844C1 (da)
DK (1) DK0773228T3 (da)
ES (1) ES2173237T3 (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19740571C1 (de) * 1997-09-15 1999-03-18 Gsf Forschungszentrum Umwelt Verfahren zur Stimulation von T-Zellen mit gewünschter Antigenspezifität
DE19816116C2 (de) * 1998-04-09 2000-06-29 Gsf Forschungszentrum Umwelt Verfahren zur Immortalisation von Zellen mit Hilfe konditional transformierter Helferzellen
AU757873B2 (en) 1998-09-14 2003-03-06 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
IL139321A0 (en) * 1999-03-03 2001-11-25 Biogen Inc Methods and compositions for modulating lipid metabolism
PL198975B1 (pl) 1999-04-22 2008-08-29 Biogen Idec Inc Zastosowanie kompozycji zawierającej homolog przeciwciała, który jest antagonistą interakcji między integryną niosącą podjednostkę alfa 4 a jej ligandem
HK1043320A1 (zh) 1999-06-01 2002-09-13 Biogen, Inc. Vla-1的一种阻塞性单系抗体，以及其治疗炎性失调的功用
UA73300C2 (en) * 1999-06-01 2005-07-15 Biogen Inc Use of composition containing homolog of antibody antagonizing interaction between integrin with alpha-4 subunit and its ligand for treating fibrosis
US7241443B1 (en) * 1999-07-15 2007-07-10 Camas Incorporated Immunogen adherence inhibitor and method of making and using same
JP2003517023A (ja) 1999-12-16 2003-05-20 バイオジェン インコーポレイテッド 中枢神経系の虚血性損傷または出血性損傷を、抗α４インテグリンアンタゴニストを用いて処置する方法
UA83791C2 (ru) * 2001-04-13 2008-08-26 Байоджен Айдек Ма Инк. Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1
EP1458855B1 (en) 2001-12-18 2012-04-25 Cancer Research Technology Limited Method for the generation of proliferating and differentiating cell lines
GB2387599B (en) * 2002-04-17 2005-08-10 Jason Peter Brown Methods for producing antibodies
UY28170A1 (es) 2003-01-24 2004-07-30 Elan Pharm Inc Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
GB2398783A (en) 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
JP2007537709A (ja) * 2003-05-23 2007-12-27 モーフオテク・インコーポレーテツド 腫瘍抗原を特異的に結合するモノクローナル抗体
DE602004029252D1 (de) 2003-06-13 2010-11-04 Biogen Idec Inc Aglycosyl-anti-cd154 (cd40-ligand) antikörper und deren verwendungen
WO2005056599A2 (en) * 2003-12-08 2005-06-23 Morphotek, Inc. Antibodies that specifically bind pms2
US20090113563A1 (en) * 2004-02-12 2009-04-30 Yoshio Umezawa Probe for detecting nuclear receptor agonist or antagonist and method for screening agonist or antagonist to nuclear receptor with the use of the same
EP1716179A2 (en) 2004-02-12 2006-11-02 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
CZ200755A3 (cs) 2004-07-26 2007-04-11 Biogen Idec Ma Inc. Peptidy protilátek anti-CD154
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
JP2008520717A (ja) 2004-11-19 2008-06-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド 多発性硬化症についての処置
US7517870B2 (en) 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
WO2006060719A2 (en) * 2004-12-03 2006-06-08 Morphotek, Inc. Use of endosialin binding proteins to isolate endosialin positive cells
US20090169477A1 (en) * 2004-12-03 2009-07-02 Michael Panzara Delaying or preventing onset of multiple sclerosis
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
BRPI0608254A2 (pt) 2005-03-02 2009-12-08 Biogen Idec Inc anticorpos kim-1 para o tratamento de condições mediadas por th2
EP2322560B1 (en) * 2005-03-10 2013-09-04 Morphotek, Inc. Anti-mesothelin antibodies
ES2440953T3 (es) 2005-03-31 2014-01-31 The General Hospital Corporation Modulación de la actividad de HGF/HGFR para tratar un linfedema
ES2640295T5 (en) 2005-04-04 2025-02-13 Biogen Ma Inc Methods for evaluating an immune response to a therapeutic agent
US20060230734A1 (en) * 2005-04-14 2006-10-19 Deere & Company, A Delaware Corporation Twin belt mule drive
AU2006241235B2 (en) * 2005-04-22 2012-04-05 Eisai, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
JP2009521206A (ja) * 2005-04-22 2009-06-04 モルフォテック、インク． 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体
ATE476986T1 (de) 2006-01-18 2010-08-15 Gen Hospital Corp Verfahren zur steigerung der lymphatischen funktion
WO2007106769A2 (en) 2006-03-10 2007-09-20 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
DE202006007499U1 (de) * 2006-05-11 2007-01-11 Osaka University Verwendung einer Zusammensetzung, die Plexin-A1-DAP12-Interaktion inhibiert, zur Behandlung von Entzündungs-, Autoimmun- oder Knochenresorptionserkrankungen
DE202006007590U1 (de) * 2006-05-12 2006-12-14 Osaka University Verwendung einer Zusammensetzung, die Sema7A- und VLA-1-Interaktion inhibiert, zum Behandeln von Cytokin-vermittelten Erkrankungen
BRPI0712607A8 (pt) 2006-05-25 2019-06-04 Biogen Idec Inc métodos de tratamento de acidente vascular cerebral
US9415111B2 (en) 2006-08-11 2016-08-16 Rutgers, The State University Of New Jersey Dual-sensitizer-containing luminescent compounds, conjugates, and uses thereof
US8288110B2 (en) * 2006-12-04 2012-10-16 Perkinelmer Health Sciences, Inc. Biomarkers for detecting cancer
WO2008112193A1 (en) 2007-03-12 2008-09-18 Dana-Farber Cancer Institute Prognostic, diagnostic, and cancer therapeutic uses of fanci and fanci modulating agents
CN101688228B (zh) * 2007-03-13 2014-12-24 国家犾太健康中心 抗体产生的方法
SG196697A1 (en) 2007-03-22 2014-02-13 Biogen Idec Inc Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
EP2620451B1 (en) 2007-04-05 2016-09-14 Morphotek, Inc. Methods for inhibiting the binding of endosialin to ligands
ES2465223T3 (es) 2007-04-27 2014-06-05 Zymogenetics, Inc. Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso
AU2007352412B2 (en) 2007-04-27 2013-05-16 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
NZ595526A (en) * 2007-06-14 2013-03-28 Biogen Idec Inc Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant
EP3293269A1 (en) 2007-08-03 2018-03-14 MUSC Foundation For Research Development Human monoclonal antibodies and methods for producing the same
SI2187967T1 (sl) 2007-08-16 2013-07-31 Irm Llc Postopki in sestavki za zdravljenje raka
AU2009228361A1 (en) * 2008-03-27 2009-10-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human anti-mesothelin monoclonal antibodies
US8591889B2 (en) 2008-04-04 2013-11-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies specific for CD22
JP2011523560A (ja) 2008-06-02 2011-08-18 ダナ−ファーバー キャンサー インスティテュート インク． Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
WO2010121141A1 (en) * 2009-04-17 2010-10-21 Biogen Idec Ma Inc. Compositions and methods to treat acute myelogenous leukemia
WO2011044553A1 (en) 2009-10-11 2011-04-14 Biogen Idec Ma Inc. Anti-vla-4 related assays
WO2011088193A2 (en) 2010-01-13 2011-07-21 University Of Medicine And Dentistry Of New Jersey Fluorophore chelated lanthanide luminiscent probes with improved quantum efficiency
EA201291065A1 (ru) 2010-04-16 2013-03-29 Байоджен Айдек Ма Инк. Антитела против vla-4
WO2012027494A1 (en) 2010-08-24 2012-03-01 Regents Of The University Of Minnesota Bispecific targeting reagents
WO2012033987A2 (en) 2010-09-09 2012-03-15 Purdue Research Foundation Anti-human folate receptor beta antibodies and methods of use
WO2013000982A1 (en) 2011-06-27 2013-01-03 Vivalis Method for screening cells
ES2732243T3 (es) 2012-02-16 2019-11-21 Santarus Inc Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
DK2828284T3 (da) 2012-03-20 2019-06-11 Biogen Ma Inc Jcv-neutraliserende antistoffer
CN103196817A (zh) * 2013-04-10 2013-07-10 哈尔滨体育学院 一种优秀冰雪运动员eb病毒转化细胞凋亡鉴定方法
WO2018140510A1 (en) 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
JP7457661B2 (ja) 2018-06-04 2024-03-28 バイオジェン・エムエイ・インコーポレイテッド 低減したエフェクター機能を有する抗ｖｌａ－４抗体

Also Published As

Publication number Publication date
ES2173237T3 (es) 2002-10-16
EP0773228A1 (de) 1997-05-14
DE19541844C1 (de) 1997-07-24
DE59609000D1 (de) 2002-05-08
US5798230A (en) 1998-08-25
EP0773228B1 (de) 2002-04-03
ATE215563T1 (de) 2002-04-15

Similar Documents

Publication Publication Date Title
DE59609000D1 (de) Verfahren zur Herstellung von menschlichen monoklonalen Antikörpern und deren Verwendung
US4634664A (en) Process for the production of human mono-clonal antibodies
CA2056102C (en) Method for the production of antibodies
Steinitz et al. EB virus-induced B lymphocyte cell lines producing specific antibody
Garzelli et al. Epstein-Barr virus-transformed lymphocytes produce monoclonal autoantibodies that react with antigens in multiple organs
IL183370A (en) Method for producing immortalized memory b lymphocytes, immortalized b cell clone made by such method and monoclonal antibody obtained from an immortalized memory b lymphocyte or immortalized b cell clone for use in diagnosis or treatment of pathogenic or viral infection
IL123025A0 (en) Human monoclonal antibody against hepatitis b virus surface antigen (HBVSAG)
DK1167537T3 (da) Fremgangsmåde til fremstilling af et monoklonalt antistof
JPH05506573A (ja) ＨＩＶ―１糖タンパクに反応性を有するＩｇＧ―１ヒトモノクローナル抗体およびその使用方法
EP0603307A4 (en) MONOCLONAL ANTIBODIES TO PUTATIVE HCV-E2 / NS1 PROTEINS AND METHOD FOR USING THEM.
AU2975697A (en) Human monoclonal antibodies to the hepatitis b surface antigen
Groves et al. Veterinary sources of nonrodent monoclonal antibodies: interspecific and intraspecific hybridomas
DE3584872D1 (de) Verfahren zur herstellung von monoklonalen antikoerpern gegen hbsag.
DK0763100T3 (da) Fremgangsmåde til rensning af Clostridium difficile-texin og fremstilling af monospecifkke antistoffer
DE59812529D1 (de) Monoklonaler Antikörper 4G8B4B12 gegen humanes FLT3/FLK2
EP0251440A3 (en) Human anti-rhesus d producing heterohybridomas
EP0131878A3 (en) Process for producing human monoclonal antibodies
IL137522A0 (en) Human monoclonal antibody against hepatitis c virus e2 glycoprotein
Stricker et al. A Human Monoclonal IgG1λ Anti‐Hepatitis B Surface Antibody: Production, Properties, and Applications
Redmond et al. The selection and characterization of human monoclonal antibodies to human cytomegalovirus
CA2095735A1 (en) Monoclonal antibodies to hepatitis c virus and method for using same
KR900700135A (ko) 광견병 비루스 세포를 특이적으로 인지하는 사람 모노클로날 항체, 이의 생성세포, 그 항체를 함유하는 제제 및 이들의 제조방법
CA1212913A (en) Human monoclonal antibodies
DE68918440D1 (de) Verfahren zur transformation von menschlichen b-lymphocyten.
CA2254931A1 (en) Human monoclonal antibodies to the hepatitis b surface antigen